Lisata Therapeutics SEC filings: 8-K
Filter: All · 8-K · 10-Q · 10-K · Form 4
Material modification of security holders' rights · Amendments to articles or bylaws; fiscal year change · Other events · Financial statements and exhibits
AI summary, unreviewedLisata Therapeutics announces one-for-fifteen reverse stock split effective November 23, 2026, cutting shares outstanding from about 10.8 million to about 0.7 million
Departure/appointment of directors or officers · Submission of matters to a vote of security holders · Other events · Financial statements and exhibits
AI summary, unreviewedLisata Therapeutics Annual Meeting Approves 2026 Equity Plan and Reverse Split Authority, But Series C Conversion Proposal Adjourned to November 30
Departure/appointment of directors or officers · Financial statements and exhibits
Entry into a material definitive agreement · Completion of acquisition or disposition of assets · Unregistered sales of equity securities · Departure/appointment of directors or officers · Amendments to articles or bylaws; fiscal year change · Regulation FD disclosure · Financial statements and exhibits
Costs of exit or disposal activities · Departure/appointment of directors or officers · Other events · Financial statements and exhibits
Termination of a material definitive agreement · Other events